Skip to content

Pediatric Phlebitis In pediatric Wards

Effect of Intravenous House Ultra Dressing in Reducing Pediatric Phlebitis In pediatric Wards :A randomized controlled trial (RCT)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20241123063810N1
Enrollment
60
Registered
2024-12-15
Start date
2024-12-01
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Phlebitis management-related intravenous cannulation.

Interventions

Intervention 1: Intervention group: After obtaining the patients consent and explaining the use of the IV House UltraDressing, the dressing is applied over the IV cannula site immediately after cannul

Sponsors

College of Nursing, University of Baghdad
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Months to 3 Years

Inclusion criteria

Inclusion criteria: 1. Pediatric patient aged 2 months to 3 years. 2. Patient with IV catheter dwell time exceeding 48 hours. 3. Intravenous therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with existing phlebitis or skin infections. 2. Patient with known allergies or reaction to the material used in the ultra-dressing. 3. Pediatric patients older than 3 years. 4. Patients with chronic vascular or immune system conditions that could influence the development of phlebitis. ents with IV catheters for less than 48 hours.

Design outcomes

Primary

MeasureTime frame
Reducing phlebitis in pediatrics. Timepoint: The patient's response is assessed for phlebitis within three days of applying the intravenous cannula dressing. Method of measurement: Phlebitis is assessed in pediatrics using the Visual Infusion Phlebitis Scale (VIPS) to assess phlebitis severity. within three days of applying the intervenous cannula dressing.

Countries

Iraq

Contacts

Public ContactRoaa Qaseem Mohammed

College of Nursing, University of Baghdad

ruaa.abd2304m@conursing.uobaghdad.edu.iq+964 781 862 5817

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026